Navigation Links
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options

PITTSBURGH, Jan. 19, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. will present pancreatic cancer data based on Precision's ChemoFx® in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, California.  

The two studies accepted by the ASCO GI are titled, InVitro Sensitivity of 5 FU and Gemcitabine in Pancreatic Cancer and Pattern of In Vitro Chemotherapy Response in Pancreatic Cancer and its Clinical Implication and will be presented by Drs. Jan Franko, Malcolm Bilimoria, Sricharan Chalikonda and David Iannitti.  The data demonstrate high (76%) in-vitro chemoresistance to traditional chemotherapy (gemcitabine or 5-FU as single agents); however, tumors resistant to one drug were not necessarily resistant to the other.  Moreover, 22% of the tumors found to be resistant to traditional single agent chemotherapy were observed to be sensitive to gemcitabine and 5-FU as a combination.  

"Traditionally, chemotherapy is selected based on the histology and site of tumor origin, but is not patient-specific.  The poor efficacy of this empirical approach is seen in daily clinical practice," says Dr. Jan Franko, lead investigator on the studies. "Our work supports the notion that the selection of chemotherapeutic agents may need to be based on the unique characteristics of a tumor sampled from patients.  ChemoFx® may assist with this by providing information on which drugs may actually be active in individual patients."

Pancreatic cancer kills an estimated 37,000 Americans per year and while recent studies on drug combinations have been promising, improvements in survival have been minimal over the past twenty-five years.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit, or

SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
2. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
3. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
5. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Precision Stability Storage Announces Upcoming Expansion
8. New statistical technique improves precision of nanotechnology data
9. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
10. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
11. Stretching single molecules allows precision studies of interacting electrons
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):